STOCK TITAN

Alpha Teknova SEC Filings

TKNO NASDAQ

Welcome to our dedicated page for Alpha Teknova SEC filings (Ticker: TKNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tracking Alpha Teknova’s intricate disclosures—ranging from reagent margin swings to modular plant capacity—can feel overwhelming. Each 10-K, 10-Q, or sudden 8-K is dense with technical language on buffers, cell-culture media, and RUO+ production grades. If you have ever searched “Alpha Teknova SEC filings explained simply” or wondered where to find the “Alpha Teknova annual report 10-K simplified,” you already know the challenge.

Stock Titan removes that barrier. Our AI reviews every Alpha Teknova quarterly earnings report 10-Q filing, highlights revenue shifts tied to Build-Tek demand, and presents concise summaries you can read in minutes. The moment an “Alpha Teknova Form 4 insider transactions real-time” notice hits EDGAR, we alert you to “Alpha Teknova executive stock transactions Form 4,” so you never miss critical moves. Need governance details? Dive into the “Alpha Teknova proxy statement executive compensation” section, with pay data automatically linked to production milestones. Our platform also offers side-by-side comparisons that make “understanding Alpha Teknova SEC documents with AI” straightforward.

Whether you’re monitoring “Alpha Teknova insider trading Form 4 transactions” ahead of a facility expansion or scanning an “Alpha Teknova 8-K material events explained” update on supply agreements, every filing is indexed seconds after release. Use our dashboards for “Alpha Teknova earnings report filing analysis,” export tables directly to your models, and rely on real-time updates across all forms. Complex biotech filings become clear, letting you focus on informed decisions—not document hunting.

Rhea-AI Summary

Alpha Teknova, Inc. (TKNO) – Form 4 insider filing dated 06/25/2025

The filing reports one transaction by Alexander Vos, a non-employee Director of Alpha Teknova. On 17 June 2025 Mr. Vos received 54,300 restricted stock units (RSUs) of common stock, coded “A” (award of securities). The RSUs were granted at a stated price of $0.00; they will vest in full on the first anniversary of the grant date (17 June 2026).

Following the award, Mr. Vos’ total reported beneficial ownership increased to 102,472 common shares, held directly. No derivative securities were involved and no shares were sold.

Implications for investors

  • The filing reflects equity-based compensation rather than an open-market purchase or sale, so cash did not change hands.
  • The incremental dilution from 54,300 shares is immaterial relative to Alpha Teknova’s outstanding share count (outstanding figure not provided in the filing).
  • The award lengthens the director’s equity exposure, which can better align board incentives with shareholder interests over the next 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Alpha Teknova, Inc. (TKNO) filed a Form 4 on 25 June 2025 detailing an equity-based compensation award to its General Counsel & Chief Compliance Officer, Damon A. Terrill. The filing reports a single grant of non-qualified stock options covering 137,808 common shares.

The option was granted on 14 February 2025 with an exercise price of $8.28 per share and a ten-year term expiring on 14 February 2035. The award vests in 48 equal monthly installments beginning one month after the grant date, aligning Mr. Terrill’s incentives with longer-term shareholder value creation. There were no open-market purchases or sales of TKNO common stock disclosed, and Mr. Terrill’s post-transaction beneficial ownership consists solely of the 137,808 derivative securities reported.

Because the transaction involves only the issuance of options rather than immediate share issuance, it has no direct impact on current share count or cash flows. However, full exercise would add up to 137,808 new shares to the outstanding share base, representing modest potential dilution. Overall, the disclosure appears to be a routine insider compensation event rather than a signal of changing fundamentals or insider sentiment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Alpha Teknova, Inc. (TKNO) – Form 4 insider filing

Director Brett Robertson reported the award of 54,300 restricted stock units (RSUs) on 17 June 2025. The award was coded “A” (acquisition) at an indicated price of $0.00, signalling that the shares were granted as part of equity compensation rather than acquired on the open market. According to the footnote, the RSUs will vest in full on the first anniversary of the grant date, subject to continued service.

Following the grant, Robertson’s aggregate direct holding increased to 102,472 common shares. He also reports an indirect ownership of 5,000 shares held in a trust, leaving his total beneficial ownership at 107,472 shares. No derivative securities transactions were reported.

This filing does not provide financial performance metrics, but the incremental equity stake modestly further aligns a board member’s incentives with shareholders. The transaction appears routine in scope and timing and does not, by itself, signal a change in corporate outlook or strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Form 4 filing summary – Alpha Teknova, Inc. (TKNO)

On 02/14/2025 the company granted Chief Financial Officer Matthew Lowell a non-qualified stock option for 169,857 common shares at an exercise price of $8.28 per share. According to the filing, the option vests monthly over 48 equal instalments beginning one month after the grant date and carries an expiration date of 02/14/2035. The transaction is coded “A” (acquired), indicating issuance by the company rather than a market purchase. No non-derivative share transactions were reported.

Following the grant, Lowell directly beneficially owns 169,857 derivative securities; no indirect ownership or additional equity awards were disclosed. The document does not provide information on Teknova’s total shares outstanding, so the potential dilution impact cannot be quantified from the filing alone. There are no sales, open-market purchases, or changes in direct share ownership, and the form contains no amendments to prior reports.

This appears to be a routine element of executive compensation intended to align the CFO’s incentives with long-term shareholder value. Because the award is subject to gradual vesting and requires an $8.28 exercise price, immediate cash outflow from the executive is not involved, nor does the option convey voting rights until exercised.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Alpha Teknova, Inc. (TKNO) filed a Form 4 on 06/25/2025 reporting an equity award to its President & CEO and Director, Stephen Gunstream.

• On 02/14/2025 Gunstream received a non-qualified stock option covering 393,663 shares of common stock at an exercise price of $8.28 per share. The award was coded “A,” indicating an acquisition by grant, and carries an exercise period that expires on 02/14/2035.

• The option vests in 48 equal monthly instalments beginning on the grant date, providing full vesting after four years. No price was paid for the option itself (reported as $0.00), consistent with standard incentive-based grants.

• After the transaction Gunstream directly holds 393,663 derivative securities and reported no indirect holdings. The filing shows no acquisition or disposition of non-derivative (actual share) securities.

This routine incentive grant strengthens management–shareholder alignment through performance-linked compensation, while also adding a potential share overhang equivalent to the optioned amount once exercised.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Alpha Teknova (TKNO)?

The current stock price of Alpha Teknova (TKNO) is $5.11 as of June 28, 2025.

What is the market cap of Alpha Teknova (TKNO)?

The market cap of Alpha Teknova (TKNO) is approximately 282.2M.

What are the primary products offered by Alpha Teknova?

Alpha Teknova offers a wide range of products including plated and liquid growth media, dry microbiological media, and an extensive selection of buffers, reagents, and solutions. Each product is available in customizable formulations to meet specific research and clinical needs.

How does Alpha Teknova support custom reagent formulations?

The company leverages its state-of-the-art modular manufacturing platform and custom configurator solutions like Build-Tek, which enables customers to design and order tailored formulations. This enables rapid turnaround and high-quality production without minimum order constraints.

What markets does Alpha Teknova serve?

Alpha Teknova serves a diverse range of customers in the life sciences industry, including academic research institutions, biotechnology companies, and pharmaceutical developers. Its products are used in microbial research, cell culture, and the development of novel therapies and diagnostics.

How does the company ensure product quality and consistency?

Quality is ensured through rigorous testing and standardized quality control assays conducted in state-of-the-art facilities. The company’s experienced team of scientists, engineers, and quality assurance experts rigorously monitor every step of the production process to guarantee consistency.

What is the significance of their Express-Tek Production and RUO+ offerings?

Express-Tek Production is designed to reduce turnaround times for custom reagents, enabling expedited delivery. RUO+ provides a bridge between research-grade flexibility and clinical-grade consistency, allowing customers to seamlessly scale from discovery research to clinical applications.

How long has Alpha Teknova been operating in the industry?

Alpha Teknova has a long-standing history in the life sciences industry, with decades of experience in innovating and manufacturing critical reagents. This extensive background underpins the company’s expertise in developing solutions that meet complex research needs.
Alpha Teknova

NASDAQ:TKNO

TKNO Rankings

TKNO Stock Data

282.17M
9.85M
9.28%
82.67%
3.11%
Drug Manufacturers - Specialty & Generic
In Vitro & in Vivo Diagnostic Substances
Link
United States
HOLLISTER